Qvision, Department of Ophthalmology of VITHAS Almería Hospital, 04120, Almería, Spain.
Fernández-Vega Ophthalmological Institute, Av. Doctores Fernández Vega, 34, 33012, Oviedo, Asturias, Spain.
BMC Ophthalmol. 2022 Aug 10;22(1):341. doi: 10.1186/s12886-022-02556-y.
The aim was to evaluate the safety and efficacy of a trifocal intraocular lens (IOL) for the correction of presbyopia and to assess patient satisfaction.
Records from three centres were reviewed to select presbyopic patients having undergone bilateral refractive lens exchange and implantation of the AT LISA tri 839MP multifocal IOL. Postoperatively, monocular and binocular distance, intermediate and near visual acuities, corrected and uncorrected, and subjective refraction were measured. Patients also completed a quality of life questionnaire. Safety evaluation included IOL stability and postoperative complications.
72 eyes (36 patients) were analysed. No clinically significant difference between pre- and postoperative corrected distance visual acuity (CDVA) was found for monocular or binocular measurements. Mean postoperative monocular CDVA was 0.02 ± 0.04 logMAR. Mean refractive values all improved statistically significantly compared with preoperative baseline (p ≤ 0.0064). Overall, 82.4% of eyes had spherical equivalent within ± 0.5 D and 97.1% within ± 1.0 D of emmetropia with a mean accuracy of -0.10 ± 0.41 D. Spectacle independence for distance, intermediate and near visual acuity was 87.5%, 84.4% and 78.1% respectively, and 78.1% of patients were satisfied with their postoperative, spectacle-free vision. Eight eyes received Nd:YAG laser treatment. No other IOL-related safety issues were reported.
AT LISA tri 839MP multifocal IOL bilaterally implanted in presbyopic patients provided excellent distance, intermediate and near visual outcomes with very accurate correction of refraction. These results were associated with a high level of spectacle independence and patient satisfaction.
Trial registered on https://clinicaltrials.gov/ under the identification NCT03790592 (31/12/2018).
本研究旨在评估三焦点人工晶状体（IOL）矫正老视的安全性和有效性，并评估患者满意度。
回顾了三个中心的病历记录，选择了接受双侧屈光性晶状体置换术并植入 AT LISA tri 839MP 多焦点 IOL 的老视患者。术后测量单眼和双眼远、中、近视力，矫正和未矫正视力，以及主观屈光度。患者还完成了生活质量问卷。安全性评估包括 IOL 稳定性和术后并发症。
72 只眼（36 例）纳入分析。单眼和双眼的术后矫正远视力（CDVA）与术前相比均无显著差异。术后平均单眼 CDVA 为 0.02±0.04 logMAR。与术前基线相比，所有平均屈光值均有统计学显著改善（p≤0.0064）。总体而言，82.4%的眼等效球镜在±0.5 D 以内，97.1%在±1.0 D 以内，平均准确性为-0.10±0.41 D。距离、中间和近视力的不戴镜率分别为 87.5%、84.4%和 78.1%，78.1%的患者对术后无需戴镜的视力感到满意。8 只眼接受了 Nd:YAG 激光治疗。未报告其他与 IOL 相关的安全性问题。
在老视患者中双侧植入 AT LISA tri 839MP 多焦点 IOL 可提供出色的远、中、近视力，且屈光矫正非常准确。这些结果与较高的脱镜率和患者满意度相关。
该试验于 2018 年 12 月 31 日在 ClinicalTrials.gov 上注册，识别号为 NCT03790592。
